Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
A Systematic Review and Meta-Analysis of the Risk of Microbial Contamination of Aseptically Prepared Doses in Different Environments
Journal of Pharmacy and Pharmaceutical Sciences, 08/31/09
Austin PD et al. – A total of 18 studies were identified for analysis. A lower rate of contamination was found in a pharmaceutical compared to clinical environments when preparing either individual or batch doses.
Related Articles
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial : The Lancet Oncology
The Lancet Oncology - Online First, 10/23/09
Relevance Score: 98%
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial
The Lancet, 11/05/09
Relevance Score: 97%
Risperidone dose for schizophrenia
Cochrane Reviews, 10/22/09
Relevance Score: 95%
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial
The Lancet, 11/23/09
Relevance Score: 94%
Antipsychotic Dose Equivalents and Dose-Years: A Standardized Method for Comparing Exposure to Different Drugs
Biological Psychiatry, 11/12/09
Relevance Score: 94%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Congenital abnormalities in children of 43 pregnant women who attempted suicide with large doses of nitrazepam
Pharmacoepidemiology and Drug Safety, 12/09/09
Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers
British Journal of Clinical Pharmacology, 12/09/09
Allos Therapeutics' FOLOTYN Shows Activity in a Dose Finding Phase 1 Study of Relapsed or Refractory Cutaneous T-Cell Lymphoma
Allos Therapeutics, 12/09/09
Sponsor
Article Search
Sponsor


See Latest Articles


